Long‐term effects of extreme smoke exposure on COVID ‐19: A cohort study
Respirology · 2024-01 · 29 (1) · 56-62
DOI: 10.1111/resp.14591 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Respirology, online erschienen am 08.09.2023. Verfasst von Tyler J Lane und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Air Pollutants, COVID-19, Air Pollution. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Health, State Government of Victoria.
Abstract (Originalsprache)
Background
In 2014, the Hazelwood coalmine fire shrouded the regional Australian town of Morwell in smoke and ash for 6 weeks. One of the fire's by‐products, PM 2.5 , is associated with an increased risk of COVID‐19 and severe disease. However, it is unclear whether the effect persisted for years after exposure. In this study, we surveyed a cohort established prior to the pandemic to determine whether PM 2.5 from the coalmine fire increased long‐term vulnerability to COVID‐19 and severe disease.
Methods
From August to December 2022, 612 members of the Hazelwood Health Study's adult cohort, established in 2016/17, participated in a follow‐up survey that included standardized items to capture COVID‐19 cases, as well as questions about hospitalization and vaccinations. Associations were evaluated in crude and adjusted logistic regression models.
Results
A total of 268 (44%) participants self‐reported or met symptom criteria for having had COVID‐19 at least once. All models found a positive association, with odds of COVID‐19 increasing by between 4% and 30% for a 10 μg/m 3 increase in coalmine fire‐related PM 2.5 exposure. However, the association was significant in only 2 of the 18 models. There were insufficient hospitalizations to examine severity ( n = 7; 1%).
Conclusion
The findings are inconclusive on the effect of coalmine fire‐related PM 2.5 exposure on long‐term vulnerability to COVID‐19. Given the positive association that was robust to modelling variations as well as evidence for a causal mechanism, it would be prudent to treat PM 2.5 from fire events as a long‐term risk factor until more evidence accumulates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Monash Rural Health Churchill, Monash University, Churchill, Victoria, Australia.
- Respiratory Medicine, The Alfred Health, Melbourne, Victoria, Australia.
- Department of Nutrition, Dietetics and Food, Monash University, Melbourne, Victoria, Australia.
- Orygen, Centre for Youth Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Tyler J Lane, Matthew Carroll, Brigitte M Borg, Tracy A McCaffrey, Caroline X Gao, Jillian Ikin, Michael J Abramson
Förderung
- Department of Health, State Government of Victoria
Zitieren
APA
Lane, T. J., Carroll, M., Borg, B. M., McCaffrey, T. A., Smith, C. L., Gao, C. X., Brown, D., Poland, D., Allgood, S., Ikin, J., & Abramson, M. J. (2024). Long‐term effects of extreme smoke exposure on COVID ‐19: A cohort study. Respirology, 29(1), 56-62. https://doi.org/10.1111/resp.14591
Vancouver
Lane TJ, Carroll M, Borg BM, McCaffrey TA, Smith CL, Gao CX, et al. Long‐term effects of extreme smoke exposure on COVID ‐19: A cohort study. Respirology. 2024;29(1):56-62. doi:10.1111/resp.14591
BibTeX
@article{Lane2024,
author = {Lane, Tyler J and Carroll, Matthew and Borg, Brigitte M and McCaffrey, Tracy A and Smith, Catherine L and Gao, Caroline X and Brown, David and Poland, David and Allgood, Shantelle and Ikin, Jillian and Abramson, Michael J},
title = {Long‐term effects of extreme smoke exposure on COVID ‐19: A cohort study},
journal = {Respirology},
year = {2024},
volume = {29},
number = {1},
pages = {56--62},
doi = {10.1111/resp.14591}
}
EUVIMED